Therapeutics News

Pilocarpine hydrochloride 1.25% administered twice daily yielded statistically greater near-vision improvements than a control vehicle, while maintaining the safety profile of once-daily administration, according to research.

Atsena Therapeutics has dosed the first patient in its open-label, phase 1/2 LIGHTHOUSE study to evaluate the subretinal ATSN-201 injection for X-linked retinoschisis, according to a company press release.

The FDA has issued a warning to consumers not to purchase and to immediately stop use of Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops because of bacterial and fungal contamination.

Ocuphire Pharma announced plans to meet with the FDA in the fourth quarter of 2023 to advance a phase 3 regulatory path for APX3330, an investigational treatment for diabetic retinopathy and diabetic macular edema.

Presbyopia is part of the body’s natural aging process, meaning that everybody who lives long enough will eventually become presbyopic.

Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.

Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Mark A. Bullimore, MCOptom, PhD, FAAO, discussed the use of atropine for myopia control in the LAMP study.

Eye care pharmaceutical company Harrow announced the launch of its next-generation compounded atropine formulations, which are now available at ImprimisRx, its compounding and mail-order pharmacy subsidiary.

The FDA has accepted a new drug application for reproxalap, an investigational new drug candidate for signs and symptoms of dry eye disease, manufacturer Aldeyra Therapeutics announced in a press release.